- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Bimagrumab - ...
MedChemExpress - Model Bimagrumab -1356922-05-8
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness[1][2].MCE products for research use only. We do not sell to patients.
Bimagrumab
MCE China:Bimagrumab
Brand:MedChemExpress (MCE)
Cat. No.HY-P99355
CAS:1356922-05-8
Synonyms:Anti-ACVR2B Reference Antibody; BYM338
Purity:99.31%
Storage:Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping:Shipping with dry ice.
Description:Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
In Vitro:BYM338 (1 pM-1 μM; 24 h) inhibits Myostatin- and Activin A-induced Smad2/3-dependent luciferase responses in HEK293 cells with IC50s of 154 and 343 pM, respectively[2]. BYM338 (4 days) prevents the inhibition of differentiation and fusion induced upon exogenous addition of Myostatin or Activin A[2].
In Vivo:BYM338 (6-20 mg/kg; s.c. once weekly for 4 weeks) promotes an increase in body weight and skeletal muscle hypertrophy of all examined muscles, slow, fast, and mixed of young SCID mice[2]. BYM338 (5-20 mg/kg; s.c. once weekly for 14 d) prevents Glucocorticoid-induced muscle wasting in mice[2].
IC50 & Target:ACVR2B 1.7 pM (Kd) ACVR2A 434 pM (Kd)
Species:Human
Isotype:Human IgG1 lambda1
Recommend Isotype Controls:Human IgG1 lambda1, Isotype Control
Hot selling product:URMC-099 | Stachydrine | Valrubicin | Cenisertib | Oil Red O | GMQ | Filanesib | Ganoderal A | BEBT-908 | AG-09/5
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References:
[1]. Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. [Content Brief]
[2]. Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606-18. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
• It has a professional experimental center and strict quality control and verification system;
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
• The biological activity of the products has been verified by the experiments of customers in various countries;
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。
